TRF1 and TRF2: pioneering targets in telomere-based cancer therapy
Journal of Cancer Research and Clinical Oncology · 16.07.2024 · 150 (7)
DOI: 10.1007/s00432-024-05867-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 16.07.2024. Verfasst von Anoop Kallingal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdansk University of Technology, Gdansk, 80-233, Poland. anoop.kallin…. Hauptthemen laut MEDLINE: Neoplasms, Telomeric Repeat Binding Protein 2, Telomeric Repeat Binding Protein 1, Telomere. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This article presents an in-depth exploration of the roles of Telomere Repeat-binding Factors 1 and 2 (TRF1 and TRF2), and the shelterin complex, in the context of cancer biology. It emphasizes their emerging significance as potential biomarkers and targets for therapeutic intervention. Central to the shelterin complex, TRF1 and TRF2 are crucial in maintaining telomere integrity and genomic stability, their dysregulation often being a hallmark of cancerous cells. The article delves into the diagnostic and prognostic capabilities of TRF1 and TRF2 across various cancer types, highlighting their sensitivity and specificity. Furthermore, it reviews current strides in drug discovery targeting the shelterin complex, detailing specific compounds and their modes of action. The review candidly addresses the challenges in developing therapies aimed at the shelterin complex, including drug resistance, off-target effects, and issues in drug delivery. By synthesizing recent research findings, the article sheds light on the intricate relationship between telomere biology and cancer development. It underscores the urgency for continued research to navigate the existing challenges and fully leverage the therapeutic potential of TRF1, TRF2, and the shelterin complex in the realm of cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdansk University of Technology, Gdansk, 80-233, Poland. anoop.kallingal@pg.edu.pl.
- Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdansk University of Technology, Gdansk, 80-233, Poland.
- Department of Medical Genetics, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
ORCID-Profile: Anoop Kallingal, Radosław Krzemieniecki, Natalia Maciejewska, Wioletta Brankiewicz-Kopcińska, Maciej Baginski
Zitieren
APA
Kallingal, A., Krzemieniecki, R., Maciejewska, N., Brankiewicz-Kopcińska, W., & Baginski, M. (2024). TRF1 and TRF2: pioneering targets in telomere-based cancer therapy. Journal of Cancer Research and Clinical Oncology, 150(7). https://doi.org/10.1007/s00432-024-05867-3
Vancouver
Kallingal A, Krzemieniecki R, Maciejewska N, Brankiewicz-Kopcińska W, Baginski M. TRF1 and TRF2: pioneering targets in telomere-based cancer therapy. Journal of Cancer Research and Clinical Oncology. 2024;150(7). doi:10.1007/s00432-024-05867-3
BibTeX
@article{Kallingal2024,
author = {Kallingal, Anoop and Krzemieniecki, Radosław and Maciejewska, Natalia and Brankiewicz-Kopcińska, Wioletta and Baginski, Maciej},
title = {TRF1 and TRF2: pioneering targets in telomere-based cancer therapy},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
volume = {150},
number = {7},
doi = {10.1007/s00432-024-05867-3}
}
EUVIMED